
Laura Turunen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7311894/publications.pdf Version: 2024-02-01



LAHDA THDHNEN

#	Article	IF	CITATIONS
1	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	9.4	334
2	Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398.	0.9	140
3	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
4	Automated Panning and Screening Procedure on Microplates for Antibody Generation from Phage Display Libraries. Journal of Biomolecular Screening, 2009, 14, 282-293.	2.6	55
5	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	3.3	39
6	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	10.3	28
7	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chemistry and Biology, 2015, 22, 1144-1155.	6.0	22
8	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. Journal of the Association for Laboratory Automation, 2016, 21, 27-36.	2.8	22
9	Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. Cancers, 2020, 12, 92.	3.7	20
10	Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells. Journal of Neuroscience Methods, 2014, 222, 142-146.	2.5	17
11	A Structural Insight into the Molecular Recognition of a (â^')-Δ9-Tetrahydrocannabinol and the Development of a Sensitive, One-Step, Homogeneous Immunocomplex-Based Assay for Its Detection. Journal of Molecular Biology, 2010, 400, 803-814.	4.2	12
12	iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacological Research, 2022, 175, 105996.	7.1	11
13	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	3.3	7
14	Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. Clinical Epigenetics, 2019, 11, 192.	4.1	1
15	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	1.4	0
16	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	1.4	0
17	Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations. Blood, 2018, 132, 2743-2743.	1.4	0